{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"limitationsAndCaveats":{"description":"At the data cut-off date, treatment with rAd-IFN had not resulted in statistically significant differences from the control group (celecoxib + gemcitabine) in the primary efficacy endpoint (OS) or secondary efficacy endpoints. The study was powered to potentially show statistical significance with 300 patients enrolled. Only 82 patients were screened and 53 were randomised."},"pointOfContact":{"email":"elisabet.gramming@ferring.com","organization":"Ferring Pharmaceuticals A/S","phone":"+ 45 88 33 88 34","title":"Elisabet Gramming"}}